XTSERVX
Market cap10mUSD
Jan 03, Last price
0.06CAD
1D
10.00%
1Q
0.00%
Jan 2017
-96.76%
Name
Resverlogix Corp
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-4m
L-85.43%
CFO
-4m
L-55.87%
Earnings
Mar 28, 2025
Profile
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada. The company is headquartered in Calgary, Canada.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2022‑12 | 2021‑12 | 2020‑12 | 2020‑04 | 2019‑04 | 2018‑04 | 2017‑04 | 2016‑04 | 2015‑04 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | 12,448 | ||||||||
Unusual Expense (Income) | |||||||||
NOPBT | (12,448) | ||||||||
NOPBT Margin | |||||||||
Operating Taxes | 18 | ||||||||
Tax Rate | |||||||||
NOPAT | (12,466) | ||||||||
Net income | (3,610) -85.43% | ||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 4,609 | ||||||||
BB yield | -12.94% | ||||||||
| Debt | |||||||||
Debt current | 6,491 | ||||||||
Long-term debt | 437 | ||||||||
Deferred revenue | |||||||||
Other long-term liabilities | 44,662 | ||||||||
Net debt | 6,888 | ||||||||
| Cash flow | |||||||||
Cash from operating activities | (3,541) | ||||||||
CAPEX | (450) | ||||||||
Cash from investing activities | (473) | ||||||||
Cash from financing activities | 4,063 | ||||||||
FCF | (6,388) | ||||||||
| Balance | |||||||||
Cash | 40 | ||||||||
Long term investments | |||||||||
Excess cash | 40 | ||||||||
Stockholders' equity | (114,264) | ||||||||
Invested Capital | 106,136 | ||||||||
ROIC | |||||||||
ROCE | 153.15% | ||||||||
| EV | |||||||||
Common stock shares outstanding | 254,423 | ||||||||
Price | 0.14 -72.55% | ||||||||
Market cap | 35,619 -70.88% | ||||||||
EV | 42,507 | ||||||||
EBITDA | (11,441) | ||||||||
EV/EBITDA | |||||||||
Interest | 1,632 | ||||||||
Interest/NOPBT | |||||||||